Symbiotec Pharmalab IPO
₹2180cr
Medium risk because:
- 5 material risk factors disclosed in DRHP
- High customer concentration flagged in the DRHP
- Intense competition in the company’s core market
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Issue Size
₹2180cr
Subscription
—
About Symbiotec Pharmalab
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
Company Details
Want to apply for this IPO?
Open a free Demat account and apply in minutes
FAQ
What is the price band of Symbiotec Pharmalab IPO?
The price band for Symbiotec Pharmalab IPO has not been announced yet. It is published in the RHP shortly before the issue opens.
What does Symbiotec Pharmalab do?
Symbiotec Pharmalab Limited is a pharmaceutical company engaged in developing and manufacturing active pharmaceutical ingredients (APIs), contract development and manufacturing (CDMO) solutions, and complex injectables. The company operates an integrated business model supported by research and development, fermentation, and organic chemistry capabilities. Its API portfolio primarily focuses on steroidal products, while its CDMO business offers development and manufacturing services for pharmaceutical, nutraceutical, and other life science companies. The company also develops complex injectable products, including double-chamber formats, and leverages its in-house API capabilities to support these offerings. Revenue is generated through the sale of APIs, CDMO services, and complex injectable products. Its business is supported by backward integration in key raw material processing, large-scale fermentation capacity, and multiple manufacturing facilities, enabling it to serve customers across regulated and global markets while expanding into new therapeutic and fermentation-based product categories.
Should I apply for Symbiotec Pharmalab IPO?
Symbiotec Pharmalab is a mainboard IPO with a ₹ price band (₹2180cr issue) — subscription data is not live yet, so demand signals are unavailable. For a mainboard IPO at moderate risk (6/10), weigh DRHP financials and sector comps against the ₹ band before you apply.